Avitar to acquire Genua:
This article was originally published in Clinica
Executive Summary
Avitar is expanding its presence in the rapid diagnostic test market with the planned stock purchase of Genua, a privately-held diagnostics company. Genua developed its Rapid Saliva Kits for HIV and hepatitis which include a custom-designed form of Avitar's Accu-sorb saliva collection devices. Genua recently revealed positive results of correlation studies for these tests, conducted at the Nassau County Medical Center, East Meadow, New York. Furthermore, Genua owns distribution rights to drugs-of-abuse and pregnancy tests. Avitar is a manufacturer of a range of healthcare products including Hydrasorbd, a line of polyurethane dressings.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.